InsiderTrades

Form 4 for IOVA IOVANCE BIOTHERAPEUTICS, INC.

Accepted 2024-07-17 00:00:00 ET · period of report 2024-07-15 · accession 0001104659-24-080619 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-07-17 2024-07-15 IOVA Vogt Frederick G GC, Interim CEO F - Tax $8.68 -8,851 159.3K -5% -$76.8K
D 2024-07-17 2024-07-15 IOVA Vogt Frederick G GC, Interim CEO M - OptEx $0.00 +20.8K 168.2K +14% $0
D 2024-07-17 2024-07-15 IOVA Vogt Frederick G GC, Interim CEO M - OptEx $0.00 -20.8K 41.7K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-07-15 F D 8,851 $8.68 159,309 D — — (F2) Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. (F3) Represents common stock remaining after deducting the common stock withheld for taxes.
2 Common Common Stock 2024-07-15 M A 20,835 $0.00 168,160 D — — (F1) Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
3 Derivative Restricted Stock Units 2024-07-15 M D 20,835 $0.00 41,669 D — · — to — 20,835 Common stock (F6) Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. (F4) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F5) The remaining RSUs will vest in equal quarterly installments.